Genetics/Genomics in chronic kidney disease--towards personalized medicine?
The progression rate of chronic kidney disease (CKD) to its terminal stage, end-stage renal disease (ESRD), and the development and severity of various complications, are at least indirectly influenced by genetic--and epigenetic--factors. For years, scientists have held out hope that the rapidly evolving field of genetics could transform medical diagnosis and treatment, moving beyond a trial-and-error approach towards "personalized medicine." Indeed, there are now signs that the role of genetics and the pursuit of "personalized medicine" in medical care will be a priority for governments during years to come. But the vision of individualized treatment based on a patient's genetic makeup and other biological markers has yet to materialize in the field of CKD and ESRD. As the toxic uremic environment may render CKD patients more sensitive to the effects of genetic variants, it is likely that genetic factors could be of special importance in this high-risk population. Therefore, outcome in the CKD population may be improved by establishing individual genetic/epigenetic profiles, thus enabling physicians to design an individualized therapeutic strategy. Personalized medicine based on a more individualized therapy could be applied in, for example, pharmacotherapy (CYP genes), dialysis therapy, and nutritional and lifestyle modifications.
Luttropp
Karin
K
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Lindholm
Bengt
B
Carrero
Juan Jesus
JJ
Glorieux
Griet
G
Schepers
Eva
E
Vanholder
Raymond
R
Schalling
Martin
M
Stenvinkel
Peter
P
Nordfors
Louise
L
D002318:Cardiovascular Diseases / Q000209:etiology; D005819:Genetic Markers; D005838:Genotype; D006801:Humans; D007674:Kidney Diseases / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D057285:Precision Medicine
D005819:Genetic Markers